Clinical Evaluation Of Serum IL-6 With Prostate Cancer And A Preliminary Study Of The Function

Background Prostate cancer is the highest incidence of non-epithelial malignancy in North America and the second leading cause of death in US men.In China,according to the National Cancer Registry in 2015 data:the incidence of prostate cancer in the male incidence rate accounted for seventh.The incidence of prostate cancer in urban areas is about 10.06/10^5,and the rural area is about 4.79/10^5.The overall mortality rate reached 2.98/10 ^ 5.In various types of tumors,inflammation and tumor formation,development,metastasis,prognosis have a certain relevance.Inflammatory cells promote tumor cell proliferation,angiogenesis,construct a microenvironment suitable for tumor growth,and induce a series of gene mutations.The main pathway is to reconstruct the extracellular matrix(ECM),mediate epithelial transdifferentiation,raise bone marrow stem cells,mediate and inhibit the immune response,and keep the tumor cells in the immune mechanism.At the same time to note that the inflammatory response and tumor microenvironment are inseparable,they together promote the formation and development of the tumor.Studies have confirmed that inflammatory factors interleukin-6(IL-6)as autocrine or paracrine growth factor,which can be directly on the tumor cells,regulate tumor growth;also by affecting the host environment,such as induction of acute phase response,Anti-apoptosis and neovascularization and so indirectly promote the growth of tumor cells.At present,the mechanism of interaction between inflammation and tumor metastasis has been explored,and it is believed that new therapeutic ideas and new therapeutic targets will be produced.Objective To study the role of IL-6 in the development and progression of prostate cancer.To investigate the correlation between serum IL-6 level and prostate cancer specific antigen,tumor stage and malignancy in patients with prostate cancer.Presumably its application value in clinical diagnosis.In addition,the effect of IL-6 on the proliferation and apoptosis of non-androgen-dependent prostate cancer cells was investigated by in vitro experiments.To further study the mechanism of IL-6 in the development and progression of prostate cancer.Methods Part I:Retrospective analysis of April 2015-2017 January,the hospital admitted to the hospital and the case of complete data in 72 patients.Including 35 newly diagnosed prostate cancer and 37 patients with age-related prostate hyperplasia as a control.(3 + 4 = 7,n= 18)and Gleason ≥ 7(4 + 3 = 7,n = 17)according to the Gleason score of prostate cancer patients.Serum levels of IL-6,PSA,blood leukocytes,neutrophils,lymphocyte count and prostate volume were measured before operation.The Gleason score and pathological stage of prostate biopsy and surgical specimens were measured.Application of statistical software SPSS 21.0 for data processing.Part II:DU145 cell lines were cultured in vitro.The cells were cultured in different concentrations of IL-6 medium,MTT assay and cell proliferation ability were measured.Cell cycle was measured by flow cytometry.To detect rhIL-6 on prostate cancer cells to promote proliferation.Result:1.prostate cancer group than the prostate hyperplasia group serum IL-6 levels higher.(P<0.05)2.PSA<10ng/ml group,the serum IL-6 level was significantly higher than>10ng/m group.(P = 0.000)3.According to Gleason score group comparison of prostate cancer patients with IL-6 differences.Gleason-7 group,the serum IL-6 value was significantly less than Gleason ≥ 7 group.(P<0.05)4.serum IL-6 and PSA,Gleason score was positively correlated.5.MTT experiments show that non-hormone-dependent prostate cancer cell proliferation rate was significantly higher than the negative control group.(P<0.05)6.Flow cytometry Annexin V method to detect cell cycle,proved rhIL-6 can promote the proliferation of DU 145.(P<0.05).Conclusion Serum IL-6 level is positively correlated with the malignant degree of prostate cancer.In prostate cancer patients,the higher the serum IL-6 level,the higher the prostate cancer Gleason score,the clinical stage later.At the same time in vitro experiments show that rhIL-6 can promote the proliferation of prostate cancer cell line DU145.